Aniline
RTECS #
BW6650000
CAS #
Updated
December 2018
Molecular Weight
93.14
Molecular Formula
C6H7N
Synonyms
Aminobenzene
Aminophen
Anilin (Czech)
Anilina (Italian, Polish)
Aniline and homologues (ACGIH:OSHA)
Aniline oil
Anyvim
Benzenamine
Benzene, amino
Benzidam
Blue Oil
C.I. 76000
C.I. Oxidation Base 1
Cyanol
Huile d'aniline (French)
Krystallin
Kyanol
NCI-C03736
Phenylamine
RCRA waste number U012
Aminophen
Anilin (Czech)
Anilina (Italian, Polish)
Aniline and homologues (ACGIH:OSHA)
Aniline oil
Anyvim
Benzenamine
Benzene, amino
Benzidam
Blue Oil
C.I. 76000
C.I. Oxidation Base 1
Cyanol
Huile d'aniline (French)
Krystallin
Kyanol
NCI-C03736
Phenylamine
RCRA waste number U012
Skin and Eye Irritation and References
| Route/Organism | Dose | Effect | Reference |
|---|---|---|---|
| eye /rabbit | 20 mg/24H | moderate | 85JCAE -,456,1986 |
| skin /rabbit | 20 mg/24H | moderate | 85JCAE -,456,1986 |
Mutation Data and Reference
| System Test | Route/Organism/Tissue | Dose | Reference |
|---|---|---|---|
| body fluid assay | Salmonella typhimurium/rat | 300 mg/kg | MUREAV 79,173,1980 |
| Cytogenetic Analysis | ovary/hamster | 444 mg/L | EMMUEG 27,67,1996 |
| Cytogenetic Analysis | fibroblast/hamster | 1000000 µg/L (+enzymatic activation step) | HPV371 -,-,2006 |
| DNA adduct | oral/rat | 1397 mg/kg/30D-continuous | TOXID9 -,345,2009 |
| DNA Damage | other cell types/rat | 1397.1 mg/kg/30D-continuous | TOXID9 -,15,2008 |
| DNA Damage | oral/rat | 1397 mg/kg/30D- intermittent | TXAPA9 233,247,2008 |
| DNA Damage | intraperitoneal/mouse | 300 mg/kg | ATSUDG 5,355,1982 |
| DNA Damage | lymphocyte/mouse | 21500 µmol/L | MUREAV 203,155,1988 |
| DNA Damage | oral/mouse | 1 gm/kg | MUREAV 440,1,1999 |
| DNA Damage | intraperitoneal/rat | 105 mg/kg | CNREA8 42,2277,1982 |
| DNA repair | /Escherichia coli | 39658 µg/well/16H | CBINA8 15,219,1976 |
| micronucleus test | intraperitoneal/mouse | 50 mg/kg | JPMSAE 80,761,1991 |
| micronucleus test | unreported route/mouse | 23 mg/kg | JAPTO* 25,514,2005 |
| micronucleus test | lung/hamster | 2500 µmol/L/6H (-enzymatic activation step) | MUTAEX 26,709,2011 |
| micronucleus test | lung/hamster | 5000 µmol/L/6H (+enzymatic activation step) | MUTAEX 26,709,2011 |
| micronucleus test | lung/hamster | 2500 µmol/L/48H (-enzymatic activation step) | MUTAEX 26,709,2011 |
| morphological transform | embryo/hamster | 485 mg/L/7D | MUREAV 755,108,2013 |
| morphological transform | fibroblast/mouse | 0.01 mg/L/21D (-enzymatic activation step) | EMMUEG 35,300,2000 |
| morphological transform | fibroblast/mouse | 800 µg/L | JJIND8 67,1303,1981 |
| mutation in mammalian somatic cells | lymphocyte/mouse | 2500 µmol/L | MUTAEX 3,193,1988 |
| mutation in mammalian somatic cells | lung/hamster | 500 µg/L | BLFSBY 39,359,1986 |
| mutation in microorganisms | /Salmonella typhimurium | 344 nmol/plate/48H (+enzymatic activation step) | MUREAV 541,123,2003 |
| mutation in microorganisms | /Salmonella typhimurium | 1 µg/plate | MUREAV 577S,1,2005 |
| mutation in microorganisms | lymphocyte/mouse | 500 µmol/L (+enzymatic activation step) | MUTAEX 3,193,1988 |
| mutation in microorganisms | /Salmonella typhimurium | 100 µg/plate (-enzymatic activation step) | PJABDW 53,34,1977 |
| sister chromatid exchange | lymphocyte/human | 300 µmol/L | MUREAV 395,159,1997 |
| sister chromatid exchange | liver/rat | 200 µmol/L | TOLED5 16,235,1983 |
| sister chromatid exchange | ovary/hamster | 50 mg/L | EMMUEG 10(Suppl 10),1,1987 |
| sister chromatid exchange | intraperitoneal/mouse | 210 mg/kg | CNREA8 42,2277,1982 |
| specific locus test | lymphocyte/mouse | 500 mg/L | EMMUEG 17,196,1991 |
Reproductive Effects Data and References
| Route/Organism | Dose | Effect | Reference |
|---|---|---|---|
| oral/mouse | 4480 mg/kg (6-13D pregnant) | Reproductive: Effects on newborn: Growth statistics (e.g., reduced weight gain) | TCMUD8 7,29,1987 |
Tumorigenic Data and References
| Route/Organism | Dose | Effect | Reference |
|---|---|---|---|
| oral/rat | lowest published toxic dose: 11 gm/kg/29W- continuous | Tumorigenic: Neoplastic by RTECS criteria Kidney, Ureter, and Bladder: Bladder tumors | APMIAL 26,472,1949 |
| oral/rat | toxic dose: 72800 mg/kg/2Y- continuous | Tumorigenic: Neoplastic by RTECS criteria Blood: Tumors | FCTOD7 25,619,1987 |
Acute Toxicity Data and References
| Route/Organism | Dose | Effect | Reference |
|---|---|---|---|
| In Vitro/Human, leukemia cells | Inhibitor Concentration (25 percent kill): 930.0 mg/L/24H | In Vitro Toxicity Studies: Cell viability (dye exclusion): trypan blue assay etc. | TIVIEQ 26,1150,2012 |
| In Vitro/Human, leukemia cells | Inhibitor Concentration (50 percent kill): 927.9 mg/L/24H | In Vitro Toxicity Studies: Other assays | TIVIEQ 26,1150,2012 |
| In Vitro/Human, lung | Inhibitor Concentration (50 percent kill): 59 gm/L/3H | In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. | TIVIEQ 27,174,2013 |
| In Vitro/Human, lung | Inhibitor Concentration (50 percent kill): 55 gm/L/24H | In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. | TIVIEQ 27,174,2013 |
| In Vitro/Human, lung | Inhibitor Concentration (50 percent kill): 64 gm/L/24H | In Vitro Toxicity Studies: Other assays | TIVIEQ 27,174,2013 |
| In Vitro/Human, lung tumor | Inhibitor Concentration (50 percent kill): 4.7 gm/L/24H | In Vitro Toxicity Studies: Cell membrane integrity: Cytoplasmic enzymes leakage (lactate dehydrogenase, ATP enzymes etc.) | TIVIEQ 27,174,2013 |
| In Vitro/Human, lung tumor | Inhibitor Concentration (50 percent kill): 4.5 gm/L/24H | In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. | TIVIEQ 27,174,2013 |
| In Vitro/Human, lymphocyte | Inhibitor Concentration (30 percent kill): >200 mg/L/45H | In Vitro Toxicity Studies: Cell viability (dye exclusion): trypan blue assay etc. | TIVIEQ 29,901,2015 |
| In Vitro/Human, lymphocyte | Inhibitor Concentration (50 percent kill): 63 mg/L/45H | In Vitro Toxicity Studies: Other assays | TIVIEQ 29,901,2015 |
| In Vitro/Human, monocyte | Inhibitor Concentration (20 percent kill): 2300 µmol/L/24H | In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. | TOLED5 199,51,2010 |
| In Vitro/Human, monocyte | Inhibitor Concentration (20 percent kill): 2.3 mmol/L/2H | In Vitro Toxicity Studies: Other assays | TOLED5 199,51,2010 |
| In Vitro/Mouse, fibroblast | Inhibitor Concentration (50 percent kill): 1.9 gm/L/24H | In Vitro Toxicity Studies: Cell membrane integrity: Cytoplasmic enzymes leakage (lactate dehydrogenase, ATP enzymes etc.) | TIVIEQ 27,174,2013 |
| In Vitro/Mouse, fibroblast | Inhibitor Concentration (50 percent kill): 1.4 gm/L/24H | In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. | TIVIEQ 27,174,2013 |
| In Vitro/Rat, liver | Inhibitor Concentration (50 percent kill): 1226 mg/L/20H | In Vitro Toxicity Studies: Cell membrane integrity: Cytoplasmic enzymes leakage (lactate dehydrogenase, ATP enzymes etc.) | TIVIEQ 5,543,1991 |
| In Vitro/Rat, liver | Inhibitor Concentration (50 percent kill): 1430 mg/L/20H | In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. | TIVIEQ 5,543,1991 |
| In Vitro/Rat, liver | Inhibitor Concentration (50 percent kill): 1226 mg/L/20H | In Vitro Toxicity Studies: Cell protein synthesis | TIVIEQ 5,543,1991 |
| In Vitro/Rat, liver | Inhibitor Concentration (50 percent kill): 920 mg/L/20H | In Vitro Toxicity Studies: Cell viability (lysosomal damage): neutral red assay etc. | TIVIEQ 5,543,1991 |
| In Vitro/Rat, liver tumor | Inhibitor Concentration (50 percent kill): 3072 mg/L/20H | In Vitro Toxicity Studies: Cell membrane integrity: Cytoplasmic enzymes leakage (lactate dehydrogenase, ATP enzymes etc.) | TIVIEQ 5,543,1991 |
| In Vitro/Rat, liver tumor | Inhibitor Concentration (50 percent kill): 2700 mg/L/20H | In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. | TIVIEQ 5,543,1991 |
| In Vitro/Rat, liver tumor | Inhibitor Concentration (50 percent kill): 2793 mg/L/20H | In Vitro Toxicity Studies: Cell protein synthesis | TIVIEQ 5,543,1991 |
| In Vitro/Rat, liver tumor | Inhibitor Concentration (50 percent kill): 4003 mg/L/20H | In Vitro Toxicity Studies: Cell viability (lysosomal damage): neutral red assay etc. | TIVIEQ 5,543,1991 |
| In Vitro/Rat, lung | Inhibitor Concentration (50 percent kill): 40.7 mmol/L/1H | In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. | TIVIEQ 32,347,2016 |
| In Vitro/Rat, lung | Inhibitor Concentration (50 percent kill): 102.3 mmol/L/1H | In Vitro Toxicity Studies: Cell membrane integrity: Cytoplasmic enzymes leakage (lactate dehydrogenase, ATP enzymes etc.) | TIVIEQ 32,347,2016 |
| In Vitro/Rat, lung | Inhibitor Concentration (50 percent kill): 70.8 mmol/L/1H | In Vitro Toxicity Studies: Cell protein synthesis | TIVIEQ 32,347,2016 |
| In Vitro/Rat, lung | Inhibitor Concentration (50 percent kill): 28.8 mmol/L/1H | Biochemical: Metabolism (intermediary): Effect on inflammation or mediation of inflammation | TIVIEQ 32,347,2016 |
| inhalation/cat | Lowest published lethal concentration: 180 ppm/8H | XPHBAO 271,4,1941 | |
| inhalation/Dog | lowest published toxic concentration: 23.6 mg/m3 | Blood: Methemoglobinemia- Carboxhemoglobinemia | TXCYAC 214,140,2005 |
| inhalation/mammal (species unspecified) | lethal concentration (50 percent kill): 2500 mg/m3 | GTPZAB 32(10),25,1988 | |
| inhalation/mouse | lethal concentration (50 percent kill): 175 ppm/7H | NTIS** PB214-270 | |
| inhalation/rat | Lowest published lethal concentration: 250 ppm/4H | JIHTAB 31,343,1949 | |
| inhalation/rat | lethal concentration (50 percent kill): 250 ppm/1H | ENTOX* -,136,2005 | |
| inhalation/rat | lowest published toxic concentration: 0.02 gm/m3/4H | Behavioral: Somnolence (general depressed activity) Behavioral: Change in motor activity (specific assay) Behavioral: Muscle weakness | TPKVAL 12,54,1971 |
| inhalation/rat | lowest published toxic concentration: 0.09 gm/m3/4H | Behavioral: Alteration of classical conditioning Vascular: Other changes Gastrointestinal: Ulceration or bleeding from stomach | TPKVAL 12,54,1971 |
| inhalation/rat | lowest published toxic concentration: 0.006 gm/m3/4H | TPKVAL 12,54,1971 | |
| intraperitoneal/guinea pig | lethal dose (50 percent kill): 100 mg/kg | TSCAT* OTS 206512 | |
| intraperitoneal/mouse | lethal dose (50 percent kill): 368 mg/kg | HPV300 -,-,2001 | |
| intraperitoneal/rat | lethal dose (50 percent kill): 420 mg/kg | AGGHAR 15,447,1957 | |
| intravenous/Dog | lowest published lethal dose: 200 mg/kg | NTIS** PB214-270 | |
| intravenous/rabbit | lethal dose (50 percent kill): 64 mg/kg | NTIS** PB214-270 | |
| oral/cat | lowest published lethal dose: 100 mg/kg | HBAMAK 4,1301,1935 | |
| oral/child | lowest published toxic dose: 3125 mg/kg | Lung, Thorax, or Respiration: Cyanosis | JTCTDW 26,357,1988 |
| oral/Dog | lethal dose (50 percent kill): 195 mg/kg | NTIS** PB214-270 | |
| oral/guinea pig | lethal dose (50 percent kill): 400 mg/kg | TSCAT* OTS 206512 | |
| oral/mammal (species unspecified) | lethal dose (50 percent kill): 500 mg/kg | GTPZAB 32(10),25,1988 | |
| oral/mouse | lethal dose (50 percent kill): 464 mg/kg | ENTOX* -,136,2005 | |
| oral/quail | lethal dose (50 percent kill): 750 mg/kg | AECTCV 12,355,1983 | |
| oral/rabbit | lowest published lethal dose: 500 mg/kg | HBAMAK 4,1301,1935 | |
| oral/rat | lethal dose (50 percent kill): 250 mg/kg | JPETAB 90,260,1947 | |
| oral/rat | lowest published toxic dose: 1118 mg/kg | Blood: Methemoglobinemia- Carboxhemoglobinemia | TPKVAL 14,118,1975 |
| oral/rat | lowest published toxic dose: 1000 mg/kg | Peripheral Nerve and Sensation: Flaccid paralysis without anesthesia (usually neuromuscular blockage) Spinal Cord: Demyelination Nutritional and Gross Metabolic: Weight loss or decreased weight gain | TOPADD 14,19,2001 |
| oral/rat | lowest published toxic dose: 1000 mg/kg | Spinal Cord: Other degenerative changes Biochemical: Metabolism (intermediary): Effect on cyclic nucleotides | TOXID9 12,470,2008 |
| oral/wild bird | lethal dose (50 percent kill): 562 mg/kg | AECTCV 12,355,1983 | |
| skin/cat | lethal dose (50 percent kill): 254 mg/kg | GTPZAB 13(5),29,1969 | |
| skin/Dog | lowest published lethal dose: 1540 mg/kg | NTIS** PB214-270 | |
| skin/guinea pig | lethal dose (50 percent kill): 1290 mg/kg | TXAPA9 7,559,1965 | |
| skin/rabbit | lethal dose (50 percent kill): 820 µL/kg | TXAPA9 7,559,1965 | |
| skin/rat | lethal dose (50 percent kill): 1400 mg/kg | ENTOX* -,136,2005 | |
| subcutaneous/cat | lowest published lethal dose: 100 mg/kg | HBAMAK 4,1301,1935 | |
| subcutaneous/mouse | lethal dose (50 percent kill): 200 mg/kg | ARZNAD 8,107,1958 | |
| subcutaneous/rabbit | lowest published lethal dose: 1 gm/kg | Lung, Thorax, or Respiration: Other changes | MELAAD 28,112,1937 |
| unreported route/man | lowest published lethal dose: 350 mg/kg | JIDHAN 13,87,1931 | |
| unreported route/man | lowest published lethal dose: 150 mg/kg | 85DCAI 2,73,1970 |
Other Multiple Dose Data and References
| Route/Organism | Dose | Effect | Reference |
|---|---|---|---|
| inhalation/rat | lowest published toxic concentration: 3 mg/m3/22W- intermittent | Blood: Changes in serum composition (e.g. TP, bilirubin, cholesterol) Blood: Other changes | GISAAA 37(5),31,1972 |
| inhalation/rat | lowest published toxic concentration: 87 ppm/6H/2W- intermittent | Liver: Changes in liver weight Endocrine: Changes in spleen weight Blood: Changes in erythrocyte (RBC) count | TOXID9 2,164,1982 |
| inhalation/rat | lowest published toxic concentration: 300 µg/m3/24H/80D- continuous | Behavioral: Muscle contraction or spasticity | GISAAA 35(4),44,1970 |
| inhalation/rat | lowest published toxic concentration: 5 mg/m3/24H/21D- continuous | Blood: Methemoglobinemia- Carboxhemoglobinemia | GISAAA 37(12),53,1972 |
| inhalation/rat | lowest published toxic concentration: 30 ppm/14D- continuous | Blood: Other hemolysis with or without anemia Blood: Methemoglobinemia- Carboxhemoglobinemia Blood: Changes in spleen | HPV371 -,,2006 |
| inhalation/rat | lowest published toxic concentration: 45 ppm/6H/27D- intermittent | Blood: Normocytic anemia | TOLED5 255,11,2016 |
| intraperitoneal/mouse | lowest published toxic dose: 894 mg/kg/6W- intermittent | Immunological Including Allergic: Autoimmune (multiple organ involvement) | TOXID9 44,187,2005 |
| oral/rat | lowest published toxic dose: 1397.1 mg/kg/30D- continuous | Blood: Changes in spleen Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Other enzymes Biochemical: Metabolism (intermediary): Other proteins | TOXID9 -,22,2008 |
| oral/rat | lowest published toxic dose: 651.98 mg/kg/7D- intermittent | Blood: Changes in spleen | TXAPA9 230,227,2008 |
| oral/rat | lowest published toxic dose: 1397 mg/kg/30D- continuous | Blood: Changes in spleen | TOXID9 -,345,2009 |
| oral/rat | lowest published toxic dose: 2200 mg/kg/20D- continuous | Endocrine: Changes in spleen weight Blood: Changes in bone marrow not included in above Related to Chronic Data: Death in the "MULTIPLE DOSE" data type field | HPV371 -,,2006 |
| oral/rat | lowest published toxic dose: 2800 mg/kg/28D- intermittent | Blood: Normocytic anemia | TOLED5 255,11,2016 |
| oral/rat | lowest published toxic dose: 700 mg/kg/7D- intermittent | Behavioral: Food intake (animal) | TOLED5 255,11,2016 |
| oral/rat | lowest published toxic dose: 700 mg/kg/7D- intermittent | Behavioral: Food intake (animal) Nutritional and Gross Metabolic: Weight loss or decreased weight gain | TOLED5 255,11,2016 |
| oral/rat | lowest published toxic dose: 913 mg/kg/2W- intermittent | Endocrine: Changes in spleen weight Nutritional and Gross Metabolic: Changes in: Fe Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Transaminases | FAATDF 25,224,1995 |
| oral/rat | lowest published toxic dose: 550 mg/kg/5D- continuous | Blood: Changes in spleen Nutritional and Gross Metabolic: Weight loss or decreased weight gain Related to Chronic Data: Death in the "MULTIPLE DOSE" data type field | FAATDF 3,285,1983 |
| oral/rat | lowest published toxic dose: 210 mg/kg/12W- continuous | Blood: Pigmented or nucleated red blood cells Blood: Methemoglobinemia- Carboxhemoglobinemia Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Other esterases | GISAAA 24(7),44,1959 |
| subcutaneous/rat | lowest published toxic dose: 900 mg/kg/6D- intermittent | Liver: Other changes Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Hepatic microsomal mixed oxidase (dealkylation, hydroxylation, etc.) Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Dehydrogenases | BCTKAG 13,99,1980 |
Reviews
| Organization | Standard | Reference |
|---|---|---|
| American Conference of Governmental Industrial Hygienists (ACGIH) | Threshold Limit Value-time-weighted average 2 ppm (skin) | DTLVS* TLV/BEI,2013 |
| American Conference of Governmental Industrial Hygienists (ACGIH) | Threshold Limit Value-Confirmed animal carcinogen | DTLVS* TLV/BEI,2013 |
| International Agency for Research on Cancer (IARC) | Cancer Review:Animal Limited Evidence | IMSUDL 7,99,1987 |
| International Agency for Research on Cancer (IARC) | Cancer Review:Animal Inadequate Evidence | IMEMDT 4,27,1974 |
| International Agency for Research on Cancer (IARC) | Cancer Review:Human Inadequate Evidence | IMSUDL 7,99,1987 |
| International Agency for Research on Cancer (IARC) | Cancer Review:Group 3 | IMSUDL 7,99,1987 |
| TOXICOLOGY REVIEW | AJMEAZ 38,409,1965 | |
| TOXICOLOGY REVIEW | TOLED5 140-141,229,2003 | |
| TOXICOLOGY REVIEW | TOLED5 140-141,183,2003 | |
| TOXICOLOGY REVIEW | TXAPA9 197,144,2004 | |
| TOXICOLOGY REVIEW | DIMON* 39,678,1993 | |
| TOXICOLOGY REVIEW | ENTOX* -,136,2005 | |
| TOXICOLOGY REVIEW | ENTOX* -,104,2005 | |
| TOXICOLOGY REVIEW | MUREAV 627,78,2007 | |
| TOXICOLOGY REVIEW | HUTOX* -,649,1996 | |
| TOXICOLOGY REVIEW | BLREV* 3,71,1989 | |
| TOXICOLOGY REVIEW | MUTAEX 23,271,2008 | |
| TOXICOLOGY REVIEW | TXAPA9 243,180,2010 | |
| TOXICOLOGY REVIEW | NTAPM* -,629,1995 | |
| TOXICOLOGY REVIEW | MUREAV 705,184,2010 | |
| TOXICOLOGY REVIEW | MUREAV 752,99,2013 | |
| TOXICOLOGY REVIEW | MUREAV 770,170,2016 | |
| TOXICOLOGY REVIEW | RTOPDW 54,247,2009 | |
| TOXICOLOGY REVIEW | RTOPDW 55,43,2009 | |
| TOXICOLOGY REVIEW | RTOPDW 55,52,2009 | |
| TOXICOLOGY REVIEW | RTOPDW 56,54,2010 |
Standards and Regulations
| Organization | Standard | Reference |
|---|---|---|
| Mine Safety and Health Administration (MSHA) STANDARD-air | time-weighted average 5 ppm (19 mg/m3) | DTLVS* 3,13,1971 |
| Occupational Exposure Limit IN ARGENTINA, BULGARIA, COLOMBIA, JORDAN check ACGIH TLV; | ||
| Occupational Exposure Limit IN SINGAPORE, VIETNAM check ACGIH TLV | ||
| Occupational Exposure Limit-ARAB Republic of Egypt | time-weighted average 2 ppm (10 mg/m3), Skin, JAN1993 | |
| Occupational Exposure Limit-AUSTRALIA | time-weighted average 2 ppm (7.6 mg/m3), JUL2008 | |
| Occupational Exposure Limit-AUSTRIA | MAK-TMW 2 ppm (8 mg/m3);KZW 10 ppm (40 mg/m3), skin, sen, 2007 | |
| Occupational Exposure Limit-BELGIUM | time-weighted average 2 ppm (7.7 mg/m3), Skin, MAR2002 | |
| Occupational Exposure Limit-DENMARK | time-weighted average 1 ppm (4 mg/m3), skin, carc, MAY2011 | |
| Occupational Exposure Limit-FINLAND | time-weighted average 2 ppm (7.7 mg/m3), short term exposure limit 4 ppm (15 mg/m3), skin, NOV2011 | |
| Occupational Exposure Limit-FRANCE | VME 2 ppm (10 mg/m3), Skin, C3 Carcinogen, FEB2006 | |
| Occupational Exposure Limit-GERMANY | MAK 2 ppm (7.7 mg/m3), skin, 2011 | |
| Occupational Exposure Limit-HUNGARY | time-weighted average 8 mg/m3, short term exposure limit 32 mg/m3, Skin, SEP2000 | |
| Occupational Exposure Limit-ICELAND | time-weighted average 1 ppm (4 mg/m3), skin, NOV2011 | |
| Occupational Exposure Limit-INDIA | time-weighted average 0.2 mg/m3, Skin, JAN1993 | |
| Occupational Exposure Limit-JAPAN | Occupational Exposure Limit 1 ppm (3.8 mg/m3), skin, s1 sen(pr), MAY2012 | |
| Occupational Exposure Limit-KOREA | time-weighted average 2 ppm (10 mg/m3), skin, 2006 | |
| Occupational Exposure Limit-MEXICO | time-weighted average 2 ppm (10 mg/m3);short term exposure limit 5 ppm (20 mg/m3) (skin), 2004 | |
| Occupational Exposure Limit-NEW ZEALAND | time-weighted average 1 ppm (4 mg/m3), skin, JAN2002 | |
| Occupational Exposure Limit-NORWAY | time-weighted average 1 ppm (4 mg/m3), JAN1999 | |
| Occupational Exposure Limit-PERU | time-weighted average 2 ppm (7.6 mg/m3), JUL2005 | |
| Occupational Exposure Limit-POLAND | MAC(time-weighted average) 5 mg/m3, MAC(short term exposure limit) 20 mg/m3, JAN1999 | |
| Occupational Exposure Limit-RUSSIA | time-weighted average 0.1 mg/m3, short term exposure limit 0.3 mg/m3, Skin, JUN2003 | |
| Occupational Exposure Limit-SWEDEN | time-weighted average 1 ppm (4 mg/m3);short term exposure limit 2 ppm (8 mg/m3), Skin, Carcinogen, JUN2005 | |
| Occupational Exposure Limit-SWITZERLAND | MAK-week 2 ppm (8 mg/m3), KZG-week 4 ppm (16 mg/m3), carc 3, skin, JAN2011 | |
| Occupational Exposure Limit-THE NETHERLANDS | MAC-TGG 1 mg/m3, Skin, 2003 | |
| Occupational Exposure Limit-THE PHILIPPINES | time-weighted average 5 ppm (19 mg/m3), Skin, JAN1993 | |
| Occupational Exposure Limit-TURKEY | time-weighted average 5 ppm (19 mg/m3), Skin, JAN1993 | |
| Occupational Exposure Limit-UNITED KINGDOM | time-weighted average 1 ppm (4 mg/m3), skin, OCT2007 | |
| Occupational Safety and Health Administration (OSHA) Permissible Exposure Limit (Construction) | 8H time-weighted average 5 ppm (19 mg/m3) (skin) | CFRGBR 29,1926.55,1994 |
| Occupational Safety and Health Administration (OSHA) Permissible Exposure Limit (Federal Contractors) | 8H time-weighted average 5 ppm (19 mg/m3) (skin) | CFRGBR 41,50-204.50,1994 |
| Occupational Safety and Health Administration (OSHA) Permissible Exposure Limit (General Industry) | 8H time-weighted average 5 ppm (19 mg/m3) (skin) | CFRGBR 29,1910.1000,1994 |
| Occupational Safety and Health Administration (OSHA) Permissible Exposure Limit (Shipyards) | 8H time-weighted average 5 ppm (19 mg/m3) (skin) | CFRGBR 29,1915.1000,1993 |
NIOSH Documentation and Surveillance
| Organization | Standard | Reference |
|---|---|---|
| National Institute for Occupational Safety and Health (NIOSH) Recommended Exposure Level TO ANILINE AND HOMOLOGS-air | Carcinogen lowest feasible conc. | NIOSH* DHHS #92-100,1992 |
| National Occupational Exposure Survey 1983 | Hazard Code 06580; Number of Industries 21; Total Number of Facilities 748; Number of Occupations 39; Total Number of Employees Exposed 41988; Total Number of Female Employees Exposed 14949 | |
| National Occupational Hazard Survey 1974 | Hazard Code 06580; Number of Industries 25; Total Number of Facilities 1868; Number of Occupations 46; Total Number of Employees Exposed 21859 |
Status in Federal Agencies
Page last reviewed: November 16, 2018
Content
source: National Institute for Occupational Safety and Health